Table 3.
Effect of ceftriaxone plus sulbactam with VRP1034 on oxidative stress parameters in cadmium exposed group after 21 days of treatment.
| Groups | Plasma | Brain | Liver | Kidney | ||||
|---|---|---|---|---|---|---|---|---|
| MDA | MPO | MDA | MPO | MDA | MPO | MDA | MPO | |
| Control group | 153.11±7.38 | 5.63±1.28 | 83.41±5.86 | 23.10±3.54 | 342.1±10.59 | 15.46±0.75 | 3.56±0.42 | 10.21±2.45 |
| Cadmium exposed group | 274.30±10.29*** | 8.44±0.98** | 115.20±6.01*** | 32.45±2.09*** | 398.5±15.44*** | 40.22±1.39*** | 0.884±0.13*** | 17.50±1.12*** |
| Ceftriaxone plus sulbactam with VRP1034 treated group | 210.64±11.52*** | 6.25±1.99* | 103.36±8.28** | 29.42±2.63ns | 361.87±8.56*** | 33.98±1.76*** | 1.96±0.22*** | 15.26±2.37ns |
All data are Mean ± SD of each group. The MDA and MPO levels were expressed in the plasma (µmol/min/ml) whereas in the tissues (µmol/g tissue). Newman-Keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group.
***
Where p<0.001 (highly significant)
**
p<0.01(significant)
*
p<0.05 (significant)
Ns
p>0.05 (non significant).